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The non-invasive evaluation of liver fibrosis is currently an active research area in hepatology 
and in the last years, liver stiffness (LS) measurement by transient elastography (TE) has been 
proposed as a rapid and non-invasive tool to evaluate the stage of chronic liver diseases (CLD). 
In our cohort of SVR patients we have found that γ-GT and BMI together with histological 
steatosis, were independently associated to high TE results by multivariate analysis, suggesting 
an important role of metabolic cofactors on the regression of liver fibrosis. We believe that our 
results add significantly to the question of the role of TE in assessing the reversal of liver fibrosis 
in SVR patients. 
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Abstract 
Background: Reversibility of advanced fibrosis after HCV-clearance is an important goal of 
therapy. 
Objectives: Measuring liver stiffness (LS) by transient elastography (TE) might be helpful in this 
setting. 
Patients and Methods: We evaluated 104 patients with biopsy-proven chronic hepatitis C (CHC) 
and sustained virological response (SVR) after Peg-Interferon (IFN) plus ribavirin since at least 
18 months. HCV-eradication was confirmed searching for serum HCV-RNA (TMA® sensitivity 
> 5-10 IU/ml). Data from literature reported the best LS cut-off values for different stages of 
liver fibrosis were 7.1 kPa for Metavir stage 2 (F2), 9.5 kPa for F3 and 12.5 for cirrhosis (F4). 
Results: TE was not reliable in four SVR obese patients. Metavir-stage of biopsy was F0-1 in 28, 
F2 in 47, F3 in 17 and F4 in eight patients. The median interval elapsed since achieving SVR 
was 36 months (range: 18-77, SD¬¬:18). Stratifying patients according to the histological stage 
assessed before treatment, a clear-cut gradient of LS values was observed from F0-1: median: 3.8 
kPa (range: 3.5-4.9) to F2: 4.6 kPa (3.8-6.0), F3: 6.2 kPa (4.8-8.6) and F4: 8.4 kPa (6.2-9.2) (P = 
0.001). Overall, 86 patients had lower values of LS than the expected LS values according to 
Metavir-stage. At multivariate logistic analysis γ-GT and histological steatosis were 
independently associated with persistence of higher values of LS. 
Conclusion: Long term responders to IFN-based therapies have lower LS values than those who 
are untreated and still viraemic. High levels of γ-GT and liver steatosis, all markers of insulin 
resistance, may hamper reduction of liver stiffness after HCV-clearance. 
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1. Background 
Evidence of either fibrotic or cirrhotic regression has now been documented in the entire 
spectrum of chronic liver diseases, including autoimmune hepatitis (1), biliary obstruction (2), 
iron overload (3), Nonalcoholic Steatohepatitis (NASH) (4, 5), and viral hepatitis (6-10). In 
patients with chronic hepatitis C, IFN-based treatment has been reported to be responsible for the 
regression of liver fibrosis in patients with sustained virological response (SVR) (10, 11). 
Diminishing fibrosis is an indication of improved long-term prognosis induced by treatment. The 
detailed histological analysis of the liver biopsies showing almost complete disappearance of 
inflammation, concomitant with lessening fibrosis scores in patients with SVR, indicates cure of 
the chronic HCV infection. Thus, not only did fibrosis not progress, but a clear-cut improvement 
in the fibrosis score in the follow-up biopsy, as compared to that taken before treatment, was 
seen in long-term responders, in contrast to the findings in patients who failed to achieve a SVR. 
Nowadays liver biopsy is still considered the gold standard for staging fibrosis. However, liver 
biopsy is no more considered as a perfect methodology because of the invasive nature of the 
procedure, sampling error and inter-observer variability (12, 13). Therefore, further alternative 
reliable strategies are needed for assessment of the hepatic status in patients with chronic liver 
diseases. In the last years, LS measurement by TE has been proposed as a rapid and non-invasive 
tool to evaluate the stage of chronic liver diseases (CLD). A strong association of LS with the 
stage of liver disease has been convincingly demonstrated in patients with chronic hepatitis (14, 
15) and a recent study has confirmed that TE is highly reproducible and characterized by an 
excellent inter and intra-observer agreement (16). For these features, TE may be helpful in 
assessing liver fibrosis in patients who achieved a SVR. 
2. Objectives 
- To assess the capability of TE to evaluate the improvement of liver damage during long-
term follow-up of patients clearing HCV after antiviral therapy with Peg-IFN plus ribavirin.  
- To identify the variables associated with the persistence of liver damage evaluated by TE 
in patients which achieved a SVR. 
3. Patients and Methods  
All patients with virological and histological diagnosis of CHC visited at Gastroenterology and 
Hepatology Unit of the University Hospital, Palermo from January 2004 to December 2007 and 
successfully treated with Peg-IFN plus ribavirin were enrolled in the study. To confirm SVR, 
HCV genome was investigated by COBAS Amplicor HCV Monitor, version 2.0; Roche or 
COBAS Amplicor HCV 2.0, sensitivity 50 IU/mL. Patients with HBV/HIV co-infection, alcohol 
abuse were excluded from the study. Biochemical and virological tests, and TE were always 
performed on the same day. Informed consent was obtained from each patient included in the 
study and the study protocol conforms to the ethical guidelines of the 1975 Declaration of 
Helsinki as reflected in a priori approval by the institution's human research committee. None of 
the patients declined to give consent. 
3.1. Clinical and Laboratory Assessment 
Clinical and anthropometric data were collected at the time of TE. BMI was calculated on the 
basis of weight in kilograms and height (in meters). A 12-hour overnight fasting blood sample 
was drawn at the time of biopsy and of TE to determine serum levels of ALT, γ-glutamyl 
transpeptidase (γ-GT), total cholesterol, HDL and LDL-cholesterol, triglycerides, ferritin, plasma 
glucose concentration, and platelet count. All patients were tested at the time of biopsy for HCV-
RNA by qualitative PCR (Cobas Amplicor HCV Test version 2.0; limit of detection: 50 IU ⁄ 
mL). HCV RNA positive samples were quantified by Versant HCV RNA 3.0 bDNA (Bayer Co., 
Tarrytown, NY, USA) expressed in IU/mL. Liver stiffness measurements were performed by 
two expert physicians (VC, AC) using TE (FibroScan, Echosens, Paris, France). Details of the 
technical background and examination procedure have been previously described (17). Up to 10 
successful measurements were performed on each patient. Success rate was calculated as the 
ratio of the number of successful measurements over the total number of acquisitions. Only those 
obtained with at least a success rate of at least 60% were considered reliable. The results are 
expressed in kilopascal (kPa). Median value of the successful measurements was the estimated 
value of liver stiffness. We assessed interobserver variability between the two operators using 15 
cases and 15 controls (15% of both cohorts) selected at random. Each physician was unaware of 
the assessments of the other one. To evaluate if the LS results were lower than expected 
according stage of fibrosis we used the previous published cut offs (F2: 7.1 kPa; F3: 9.5 kPa and 
F4: 12.5) (14). 
3.2. Liver Histology 
Liver biopsies performed before antiviral treatment was reevaluated by a single pathologist 
blinded from previous histological, clinical and biochemical results. The liver fibrosis stage was 
reported using a five-point (F0 –F4) scale: Stage F0 indicated absence of fibrosis; F1 expressed 
portal fibrosis without septa; F2 was equal to portal fibrosis with a few septa; F3 indicated 
numerous septa without cirrhosis; and F4 was equivalent to liver cirrhosis. The percentage of 
hepatocytes containing macrovescicular fat was determined for each 10x field. An average 
percentage of steatosis was then determined for the entire specimen. Steatosis was assessed as 
the percentage of hepatocytes containing fat droplets (minimum 5%), and evaluated as a 
continuous variable. Steatosis was classified as: mild 5%-30% or moderate-severe ≥ 30%.  
3.3. Statistical Analysis  
Data were collected with a predefined pro-forma. Continuous variables were summarized as 
mean and standard deviation and categorical variables as frequency and percentage. Differences 
in the means were evaluated by an unpaired Student t-test and the Chi-squared test was applied 
to categorical variables. Spearman correlation analysis was used to assess the relationships 
between biochemical, virological, histological variables and TE. Significant variables on 
univariate analysis (P < 0.05) were included in multivariate model. Multiple logistic regression 
models were used to assess the demographic, virological, metabolic, instrumental and 
histological characteristics of patients associated to the persistence of high value of liver 
stiffness. All statistical analyses were performed with SPSS 17.0 (SPSS, Chicago, IL). 
4. Results 
One hundred and four consecutive patients with chronic hepatitis C diagnosed between January 
2004 to December 2006 at Gastroenterology and Hepatology Unit of the University Hospital of 
Palermo and treated with Peg-IFN plus Ribavirin obtaining a SVR was enrolled in the study. 
Four patients had an unreliable TE due to obesity (BMI > 30). Table 1 shows the demographic, 
clinical and histological characteristics of SVR cohort. There were 54 male patients and mean 
age was 56.2 ± 11.8 years. Mean value of BMI was 27.8 ± 4.0 Kg/h2. Mean total cholesterol and 
triglycerides values were 192.5 ± 36.5 mg/dl and 120.1 ± 56.7 mg/dl respectively. To assess the 
presence of insulin resistance we evaluated the triglycerides/glucose index (TyG). Mean value of 
TyG was 4.62 ± 0.24. As expected, mean values of aminotransferases, γ-GT, bilirubin and 
platelets count were in normal ranges. The distribution of Metavir histological stages at liver 
biopsy performed before antiviral treatment in SVR patients was the following: stage F0-F1 was 
reported in 28 patients (28%), F2 in 47 (47%), and F3 in 17 (17%). Finally, 8 patients (8%) were 
classified as having cirrhosis (Metavir stage = 4). Histological steatosis was found in 24% of 
patients.  
4.1. TE Data Analysis 
Using the LS cut-offs values for different stage of liver fibrosis reported in the Castera et al study 
(14) we found that in 86 patients (86%), TE results were lower respect the referral cut-offs 
values defined for the different Metavir stages. In particular, a TE value lower than 7.1 kPa was 
observed in 66 of the 76 (86.8%) patients with Metavir stage ≤ 2, 13 out of 17 SVR patients 
(76.5%) who had severe fibrosis (Metavir stage 3) had a TE value lower than 9.5 kPa and finally, 
in all eight patients with cirrhosis the TE value in the follow up was lower than 12.5 kPa (100%). 
4.2. Variables Related to TE in SVR Patients 
By univariate linear regression analysis TE was significantly correlated with γ-GT, platelets, 
Metavir stage and BMI. The variables independently associated with TE as continuous variables 
were only Metavir stage and BMI by multivariate linear regression analysis (Table 2).  
4.3. Variables Associated With Persistence of High TE Values 
Since in 14 patients we have observed a persistently high value of TE despite the SVR, we 
analyzed if some clinical variables may predict the persistence of high value of TE in these 
patients. Univariate and multivariate logistic regression analyses were performed to identify the 
variables associated to the persistence of high values of TE in patients with SVR. At univariate 
analysis the absence of reduction of TE was associated with BMI, γGT and histological steatosis. 
Age, diagnosis of diabetes and Metavir stage were marginally associated to high TE values at 
univariate analysis and included in the multivariate model. Histological steatosis (OR 2.80, 
95%CI 1.000 – 12.52; P = 0.050) and γ-GT (1.06 95%CI 1.01-1.12; P = 0.014), remain the 
unique variables independently associated to permanence of high TE at multivariate analysis. 
(Table 3). Excluding steatosis and Metavir stage from the model, since they could be verified 
only by biopsy, a model was obtained that included γ-GT (OR 1.07; 95%CI 1.01 - 1.13; P = 
0.041) and BMI (OR 1.22; 95%CI 1.01 - 1.50; P =0.045) as indirect predictors of higher TE 
values (Table 4).  
5. Discussion 
TE is a non-invasive device designed to predict liver fibrosis. This methodology is currently 
subject to extensive validation in cross-sectional and longitudinal studies but, currently, its role 
in the evaluation of regression of liver fibrosis has not been extensively studied. The present 
study have shown a significant reduction of the mean values of LS in the SVR patients respect 
the best TE cut off values reported in literature in patients infected by HCV. This confirmed the 
results observed by Ogawa et al. (18) who demonstrated that the liver elasticity of SVR patients 
markedly improved over time. However, the reasons of this phenomenon are not completely 
understood. In fact, we already know that TE measurement is strongly influenced by liver 
inflammation (19-21), thus the reduction of liver stiffness value could be entirely correlated to 
the decrease of activity in the liver. On the other side, many previous reports have shown that 
IFN treatment achieves biochemical and histological improvement with viral suppression in 
patients with CHC (9, 11, 22-24). Several potential mechanisms have been hypothesized for the 
anti-fibrotic effect of IFN, including that IFN alpha can directly reduce fibrogenesis (9, 10). Thus 
TE in this cohort detected a reduction of the fibrosis amount in the liver and taking into account 
that liver biopsy has not been recommended in patients who achieve SVR, it has a useful role in 
the assessment of the correlation between liver stiffness and liver fibrosis in the no longer active 
viral disease. Further studies should be performed with the aim to asses if in cirrhotic patients 
undergoing antiviral therapy TE may have a role in a noninvasive prognostic evaluation of 
advanced liver disease and to evaluate any clinical differences between patients who achieve the 
reduction of liver stiffness in comparison with those without SVR. Another aim of our study was 
evaluate the demographic, clinical and histological variable associated to a persistence of high 
TE value in patients with SVR after IFN based treatment. It is well known from literature that 
Insulin Resistance (IR), a feature exceedingly common in patients with CHC (25-28), 
particularly in genotype 1 (G1) infection (26), can be considered a putative candidate for 
influencing LSM variations. In this setting, IR has been systematically associated not only with 
liver steatosis, but also with severe fibrosis (26-28), portal hypertension (29, 30) and, ultimately, 
with the mechanisms leading to collagen deposition, vasoconstriction, and regulation of 
sinusoidal structure (31-34). Therefore, insulin, interfering with all the above cited mechanisms, 
could influence liver stiffness. Poynard et al. (9) have shown that the factors associated with a 
regression of liver fibrosis for patients with chronic HCV after antiviral therapy are baseline 
fibrosis stage, baseline activity, SVR, BMI, age and viral load. In our study we have observed 
that the by univariate analysis, the 14 SVR patients with persistently higher liver stiffness value 
had a significantly higher γ-GT and BMI values and an higher prevalence of diabetes and liver 
steatosis at liver biopsy respect the other 86 patients. Excluding histological steatosis, taking into 
account that we need on a non-invasive assessment of liver damage in this category of patients, 
we have found that only γ-GT and BMI were independently associated to high TE results by 
multivariate analysis, suggesting an important role of metabolic cofactors on the regression of 
liver fibrosis which can be measured also by TE. This study has some limitations. First, the 
analysis was carried out in a relatively small number of patients, and it would be interesting to 
see if these results also hold true in larger groups of patients with CHC who obtain SVR. Second, 
our study included a cohort of European, non-drinker patients with a low prevalence of obesity 
and cirrhosis, who were enrolled in a tertiary referral center for liver disease, limiting the broad 
application of the results. Third, our patients started antiviral therapy when TE was not available. 
Therefore we used well established TE cutoff values of different fibrosis stages to evaluate the 
changes of LS values at the end of follow-up. A further methodological limitation could reside in 
the accuracy of liver biopsy examination for assessing fibrosis, which is universally defined as 
“gold standard”. However, it is widely known that liver biopsy should be considered a “reference 
standard”, because of the limitations previously discussed. In conclusion, our results show that 
transient elastography is a useful tool for the longitudinal assessment of IFN treatment of chronic 
hepatitis C patients and that in CHC patients who eradicate HCV it may help the clinicians for 
the assessment of the outcome of these patients and to identify and treat the cofactors. 
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Table 1. Demographic, Clinical and Histological Features of CHC Patients With Sustained 
Virological Response (SVR) 
 SVR patients (N = 100) 
Males, No. (%) 54 (54.0) 
Age, y, mean ± SD 56.2 ± 11.8 
Total Bilirubin, mg/dl, mean ± SD 0.8 ± 0.3 
AST, IU/l mean ± SD 19.8 ± 6.8 
ALT, IU/l mean ± SD 20.5 ± 10.3 
Platelet count x 10
3
/mmc, mean ± SD 220.3 ± 67.2 
γ -GT, IU/l, mean ± SD 21.4 ± 14.6 
Total Cholesterol, mg/dl, mean ± SD 192.5 ± 36.5 
Triglycerides, mg/dl, mean ± SD 120.1 ± 56.7 
TyG test, mean ± SD 4.62 ±  0.24 
Diabetes, No. (%) 9 (9.0) 
Body mass index (mean ± SD) 27.8 ± 4.0 
Genotype 1/4 72 
Genotype 2/3  28 
HCV-RNA, UI/mL, mean ± SD _ 
Stage of fibrosis (Metavir score), No. (%)  
0-1 28 (28.0) 
2 47 (47.0) 
3 17 (17.0) 
4  8 (8.0) 
Grade of inflammation (Metavir score), No. (%)  
1   28 (28.0) 
2    46 (46.0) 
3 26 (26.0) 
Histological steatosis  24 (24.0) 
 
  
Table 2. Spearman Correlation Analysis of Liver Stiffness With Clinical Variables in 100 CHC 
Patients With SVR 
 Univariate Analysis Multivariate Analysis  
Correlation 
coefficient 
P value β a S.E. P value 
Age 0.087                                             0.4    
AST 
a a
 0.108                                             0.3    
ALT 
a
 0.182                                             0.1    
γ-GT a 0.400                                         < 0.001 0.026            0.017             0.1
Platelet count -0.315                                         0.014 -0.004           0.004             0.3
Total Cholesterol 0.002                                             0.9    
Tyg 
a
 0.181                                             0.1    
Stage of Fibrosis (Metavir Score) 0.475                                        < 0.001 0.943            0.302            0.003 
Body mass index 0.286                                           0.010 0.179            0.073             0.018 
a 
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase, β, x; γ-GT: 
gamma-glutamyl-transpeptidase; TyG: triglycerides/glucose index 
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Table 3. Logistic Regression Analysis of Variables Associated to Persistently High Value of 
Liver Stiffness (LS) in 100 Patients With CHC and SVR 
Variable Not improved 




, (n = 
86) 
P value O.R. (95% 
C.I.) 
P value 
Male gender, No. (%) 9 (64.3) 43 (50.0) 0.41   
Age, y, Mean ± SD 60.8 ± 8.3 55.6 ± 12.3 0.07 1.02 (0.95-




, Mean ± SD 17.7 ± 4.4 20.1 ± 7.2 0.33   
ALT, 
a
 Mean ± SD 19.6 ± 7.4 20.3 ± 10.7 0.79   
γ GT a, Mean ± SD 37.2 ± 23.7 21.9 ± 14.3 0.04 1.06 (1.01-
1.12)           
0.014 
Platelet count, Mean ± SD 205.0 ± 33.6 217.9 ± 73.8 0.65   
Total Cholesterol, Mean ± 
SD 





8 (57.1%) 39 (45.3%) 0.28   
Body mass index, Mean ± 
SD 
29.8 ± 5.4 27.1 ± 3.4 0.03 1.19 (0.96-
1.47)           
0.101 
Diabetes, No. (%) 3 (21.4%) 4 (4.6%) 0.08 4.04 (0.43-
38.04)       
0.223 
Stage of fibrosis (Metavir 
score), No. (%) 
     
0-1 1 (7.1) 27 (31.4) 0.052 1.25 (0.54-
2.92)          
0.605 
2 9 (64.3) 38 (44.2)    
3 4 (28.6) 13 (15.1)    
4 0 8 (9.3)    
Steatosis  6 (42.8) 16 (18.6) 0.03 2.80 (1.00-
12.52)        
0.050 
a 
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GT, 
gamma-glutamyl-transpeptidase 
b
 (TyG ≥ 4.6) 
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Table 4. Logistic Regression Analysis of Variables Associated to Persistently High Value of 
Liver Stiffness in CHC Patients With SVR, Histological Variables Were Excluded From the 
Model 
Variable Not improved 
LS 
a
, (n = 13) 
Improved 







Male gender, No. (%) 9 (64.3) 43 (50.0) 0.41   
Age, y, Mean ± SD 60.8 ± 8.3 55.6 ± 12.3 0.07 1.01 (0.94-




, Mean ± SD 17.7 ± 4.4 20.1 ± 7.2 0.33   
ALT 
a
, Mean ± SD 19.6 ± 7.4 20.3 ± 10.7 0.79   
γ-GT a, Mean ± SD 37.2 ± 23.7 21.9 ± 14.3 0.04 1.07 (1.01-
1.13)                    
0.041 
Platelet count, Mean ± SD 205.0 ± 33.6 217.9 ± 73.8 0.65   
Total cholesterol, Mean ± SD 193.4 ± 38.5 192.5 ± 34.9 0.91   
Insulin resistance 
b
, No. (%) 8 (57.1) 39 (45.3) 0.28   
Body mass index, Mean ± 
SD 
29.8 ± 5.4 27.1 ± 3.4 0.03 1.22 (1.01-
1.50)                    
0.045 
Diabetes, No. (%) 3 (21.4) 4 (4.6) 0.08 3.40 (0.42-
27.82)                  
0.254 
a 
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GT, 
gamma-glutamyl-transpeptidase 
b
 TyG ≥ 4.6 
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